Re-Aim Therapeutics

Private

OxfordHealthcare & Life Scienceshttps://re-aimtx.com/

Last Round

Seed

May 18, 2026

Total Funding Raised

$9.4M

Company Overview

Re-Aim Therapeutics is a biotechnology company that develops targeted biologics to treat autoimmune diseases by selectively depleting pathogenic T cell subsets.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologymonoclonal antibodydrug discoveryautoimmune diseasebiologicsepitope targetingT cell therapytherapeutic candidatechronic inflammationbiotech startuppre-clinical researchpsoriasis treatmentpsoriatic arthritishidradenitis suppurativa

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Re-Aim Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Re-Aim Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Re-Aim Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Seed	May 18, 2026

View all Funding Rounds

Re-Aim Therapeutics Investors

Notable investors and investment history

Re-Aim Therapeutics investors
Investor	Rounds
Syncona	Seed
Oxford Science Enterprises	Seed

View all Investors

Re-Aim Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Re-Aim Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Re-Aim Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford

Year Founded2024

Last FundingMay 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.